Prices from £99 (100μg ) – For larger quantities, please contact us.
Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (MAb Anti-VEGF 165A)
Product description: Recombinant humanized mouse monoclonal antibody against VEGF 165A, produced in Nicotiana benthamiana by Agrobacterium-mediated transient expression.
Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (MAb Anti-VEGF 165A) (bevacizumab)
Product description: Recombinant humanized mouse monoclonal antibody against VEGF 165A, produced in Nicotiana benthamiana by Agrobacterium-mediated transient expression, (bevacizumab).
Host species: Nicotiana benthamiana
Molecular weight: 150 kDa (light chain; 25 kDa, heavy chain 50 kDa)
Tag: No tag
Uses: For research use only. For in vitro use only. Examples include SDS-PAGE, Western Blot, functional assays.
Relevance: VEGF1 promotes growth of new blood vessels, known as angiogenesis.2 In cancer, most tumors show elevated levels of VEGF due to the increased need for oxygen from cells involved in tumor growth. The imbalanced level of VEGF thus encourages blood vessel growth to the tumor. The new blood vessel structure, or vasculature, tends to be disorganized and non-functional, limiting drug delivery and can lead to promotion of cancer cell metastatisation.2 Treatments targeting VEGF imbalance in tumor growth have involved inhibition of angiogenesis using agents such as monoclonal antibodies (MAb anti-VEGF) against VEGF. Binding of MAb anti-VEGF causes a steric pathway block, preventing binding of VEGF to its receptors. Counterintuitive treatment strategies have used low doses of MAb VEGF to promote transient normalization of tumor vasculature to improve vasculature functionality rather than destroying tumor blood vessels.3 With improved vasculature function, drug delivery efficacy is increased within a certain time scale and the risk of hypoxia and metastatisation is reduced.4
Purity: >90 % as shown by SDS-PAGE.
Figure 1: 4-20% SDS-PAGE analysis of 5 µg Anti-VEGF 165A, reducing (R) and non-reducing (NR).
Biological activity: Measured SPR affinity for VEGF 165A: KD (M): 1.46 E-11
Endotoxin: < 1 EU/mg prior to lyophilization.
Formulation: Lyophilized from 50 mM Sodium Phosphate pH 6.2, 175 mM Trehalose Dihydrate and 0.04% Tween-20.
Shipping: Recombinant proteins are sterile-filtered and provided as lyophilized powder which are shipped at ambient temperature.
Stability & Storage: See COA for detailed storage instructions. Lyophilized materials are stable for up to twelve months from date of receipt at -70℃.
It is recommended that reconstituted protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution: A hardcopy of COA with reconstitution instructions is included with the product.
Contact us for more information.
- Sara Petrillo, Emanuela Tolosano, Luca Munaron and Tullio Genova, Targeting Metabolism to Counteract Tumor Angiogenesis: A Review of Patent Literature, Recent Patents on Anti-Cancer Drug Discovery (2018) 13: 422.
- Rakesh K Jain, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science. 2005 Jan 7;307(5706):58-62.
- Paxton V. Dickson, John B. Hamner, Thomas L. Sims, Charles H. Fraga, Catherine Y.C. Ng, Surender Rajasekeran, Nikolaus L. Hagedorn, M. Beth McCarville, Clinton F. Stewart and Andrew M. Davidoff, Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy Clin Cancer Res July 1 2007 (13) (13) 3942-3950